Amgen licenses pain drug to J
From Times Wire Services
Amgen Inc. agreed to license an experimental pain drug to Johnson & Johnson for $50 million initially and as much as $385 million in additional payments.
The agreement would give J&J;, which is based in New Brunswick, N.J., global rights to the drug everywhere except Japan, Amgen said.
The compound from Amgen, which is based in Thousand Oaks, is a fully human anti-nerve growth factor antibody, the statement said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
